Aryastha showcased its innovative technology platform, BioSolution®, at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland, USA. Chief of Aryastha’s Clinical team Dr. Gnaeswar Atturu, MD, FRCP, delivered a podium presentation on the use of Patient Tumor-Derived Organoids to predict clinical outcomes and understand the mechanisms of action of targeted therapies and immune checkpoint inhibitors. Head of Biology, Dr. Suman Dutta, PhD, also presented the BioSolution platform’s application in Integrated Drug Development (IDD) process to facilitate shorter time and better route for clinical success. His poster received high recognition, ranking 150th out of 1,350 posters submitted at the event.
The sessions and booth attracted hundreds of scientists from the biotech, academic, and pharmaceutical sectors, all expressing strong interest in leveraging the BioSolution platform for their own drug development efforts.
Chief Scientific Advisor Dr. Pradip K Majumder, PhD and Chief Executive Officer Dr. Raghav Reddy Kethiri, PhD have also joined the team for strategic discussion with biopharma partners.
